A Sansone1,2, M Sansone3, R Selleri3, A Schiavo3, D Gianfrilli3, C Pozza3, M Zitzmann4, A Lenzi3, F Romanelli3. 1. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy. andreasansone85@gmail.com. 2. Department of Clinical and Surgical Andrology, Center of Reproductive Medicine and Andrology, University of Münster, Münster, Germany. andreasansone85@gmail.com. 3. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy. 4. Department of Clinical and Surgical Andrology, Center of Reproductive Medicine and Andrology, University of Münster, Münster, Germany.
Abstract
PURPOSE: Testosterone replacement therapy (TRT) is recommended for the treatment of most cases of male hypogonadism. Transdermal testosterone (T) gels are commonly used in clinical practice; however, there is little evidence concerning how to monitor dosage to bring and maintain serum T levels in the normal physiologic range. METHODS: We examined 30 hypogonadal patients undergoing treatment with 40 mg/day transdermal 2% testosterone gel. After a week from treatment onset, all patients underwent a total of four measurements to assess serum total T, bioavailable T and free T at + 2 h (samples A and A') and + 23 h (samples B and B'). RESULTS: No significant difference was found concerning total, free and bioavailable T between the two samples taken at the same time points (A vs A' and B vs B'). A repeated-measures mixed effects regression model showed significantly lower serum levels of total, free and bioavailable T at + 23 h compared to + 2 h (total T, β = - 3.050 ± 0.704, p < 0.001; free T, β = - 85.187 ± 22.746, p < 0.001; bioavailable T, β = - 1.519 ± 0.497, p = 0.003) without a significant between-sample variability. Serum T > 3.5 ng/ml at + 2 h was reached in 21/30 patients (70%), but only 11 (36.7%) still had adequate serum T at + 23 h. CONCLUSION: Assessment of TRT with transdermal gels at its peak and at its minimum could be useful in providing a finely tailored treatment for hypogonadal men, both preventing supra-physiological levels and maintaining adequate concentrations through the day.
PURPOSE:Testosterone replacement therapy (TRT) is recommended for the treatment of most cases of male hypogonadism. Transdermal testosterone (T) gels are commonly used in clinical practice; however, there is little evidence concerning how to monitor dosage to bring and maintain serum T levels in the normal physiologic range. METHODS: We examined 30 hypogonadal patients undergoing treatment with 40 mg/day transdermal 2% testosterone gel. After a week from treatment onset, all patients underwent a total of four measurements to assess serum total T, bioavailable T and free T at + 2 h (samples A and A') and + 23 h (samples B and B'). RESULTS: No significant difference was found concerning total, free and bioavailable T between the two samples taken at the same time points (A vs A' and B vs B'). A repeated-measures mixed effects regression model showed significantly lower serum levels of total, free and bioavailable T at + 23 h compared to + 2 h (total T, β = - 3.050 ± 0.704, p < 0.001; free T, β = - 85.187 ± 22.746, p < 0.001; bioavailable T, β = - 1.519 ± 0.497, p = 0.003) without a significant between-sample variability. Serum T > 3.5 ng/ml at + 2 h was reached in 21/30 patients (70%), but only 11 (36.7%) still had adequate serum T at + 23 h. CONCLUSION: Assessment of TRT with transdermal gels at its peak and at its minimum could be useful in providing a finely tailored treatment for hypogonadal men, both preventing supra-physiological levels and maintaining adequate concentrations through the day.
Entities:
Keywords:
Male hypogonadism; Monitoring; Testosterone gel; Testosterone replacement therapy
Authors: Giulia Rastrelli; Federica Guaraldi; Yacov Reismann; Alessandra Sforza; Andrea M Isidori; Mario Maggi; Giovanni Corona Journal: Sex Med Rev Date: 2019-02-22
Authors: Giovanni Corona; Elisa Maseroli; Giulia Rastrelli; Andrea M Isidori; Alessandra Sforza; Edoardo Mannucci; Mario Maggi Journal: Expert Opin Drug Saf Date: 2014-08-19 Impact factor: 4.250
Authors: Farid Saad; Antonio Aversa; Andrea M Isidori; Livia Zafalon; Michael Zitzmann; Louis Gooren Journal: Eur J Endocrinol Date: 2011-07-13 Impact factor: 6.664
Authors: William D Finkle; Sander Greenland; Gregory K Ridgeway; John L Adams; Melissa A Frasco; Michael B Cook; Joseph F Fraumeni; Robert N Hoover Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240
Authors: A M Isidori; G Balercia; A E Calogero; G Corona; A Ferlin; S Francavilla; D Santi; M Maggi Journal: J Endocrinol Invest Date: 2014-11-11 Impact factor: 4.256
Authors: Alexander W Pastuszak; Marc Gittelman; James P Tursi; Jonathan S Jaffe; David Schofield; Martin M Miner Journal: Andrology Date: 2021-10-08 Impact factor: 4.456